Sjögren-szindróma: vizsgálatok itt: Kína
30 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleTwo Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden
- Where
- Beijing, Chengdu, Jiujiang, Nanjing, Ningbo, Shenzhen, Taiyuan, Wenzhou
- Életkor
- 18 év and over
- People
- 570 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07621809 · EU 2025-522271-29-00 - 2. fázisTaking peopleA Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
- Where
- Beijing, Hefei, Nanjing, Taiyuan
- Életkor
- 18 év to 100 év
- People
- 344 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07737743 · EU 2025-524513-92-00 - No phaseNot yet taking people in KínaMYTP01 for Immune-Mediated Diseases
- Where
- Hangzhou
- Életkor
- 18 év to 65 év
- People
- 160
- Run by
- Zhejiang Provincial People's Hospital
See details and how to joinNCT07901764 - 1. fázisTaking peopleA Study of ATG-201 in Adult Participants With Autoimmune Diseases
- Where
- Beijing, Bengbu, Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Luoyang, Nanjing, Shanghai, Suzhou, Taiyuan, Wuhan, Xiamen, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 149
- Run by
- Antengene Biologics Limited
See details and how to joinNCT07732309 - No phaseTaking peopleAn Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 6
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06379646 - 1. fázisTaking peopleA Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 12
- Run by
- Therorna
See details and how to joinNCT07413341 - No phaseTaking peopleClinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 60
- Run by
- Peking University People's Hospital
See details and how to joinNCT07843381 - Korai 1. fázisTaking peopleClinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 10
- Run by
- Peking University Third Hospital
See details and how to joinNCT07301164 - 2. fázisNot yet taking people in KínaA Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease
- Where
- Hefei
- Életkor
- 18 év to 75 év
- People
- 198
- Run by
- Innovent Biologics (Suzhou) Co. Ltd.
See details and how to joinNCT07836660 - 1/2. fázisTaking peopleSafety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 9
- Run by
- Peking University Third Hospital
See details and how to joinNCT06828042 - Korai 1. fázisNot yet taking people in KínaCD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680 - Korai 1. fázisTaking peopleMTS109 in Patients With Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Shanghai Changzheng Hospital
See details and how to joinNCT07526350 - 1. fázisNot yet taking people in KínaCM336 for Active Sjogren's Syndrome Study
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 30
- Run by
- Keymed Biosciences Co.Ltd
See details and how to joinNCT07642843 - Korai 1. fázisTaking peopleClinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
- Where
- Bengbu
- Életkor
- 18 év to 70 év
- People
- 20
- Run by
- Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT06548607 - 1. fázisTaking peopleAn Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
- Where
- Bengbu
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236762 - 1/2. fázisTaking peopleUmbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
- Where
- Beijing
- Életkor
- 6 év to 65 év
- People
- 45
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06947473 - 1. fázisTaking peopleExploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
- Where
- Xuzhou
- Életkor
- 18 év to 65 év
- People
- 18
- Run by
- China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07236801 - 1. fázisNot yet taking people in KínaYTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 5 év to 18 év
- People
- 12
- Run by
- Children's Hospital of Fudan University
See details and how to joinNCT07439029 - No phaseNot yet taking people in KínaA Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
- Where
- Tianjin
- Életkor
- 18 év to 65 év
- People
- 24
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07212322 - 1/2. fázisTaking peopleAnalyse of Inflammatory Activity of Sjögren's Syndrome on 68Ga-FAPI PET-CT
- Where
- Beijing
- Életkor
- 18 év to 80 év
- People
- 60
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07062523 - No phaseNot yet taking people in KínaA Study of Yiqi Yangyin Formula in the Treatment of Primary Sjogren's Syndrome
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 105
- Run by
- China-Japan Friendship Hospital
See details and how to joinNCT07145060 - 1/2. fázisTaking peopleChimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
- Where
- Shanghai
- Életkor
- 18 év to 70 év
- People
- 6
- Run by
- Bangdong Gong
See details and how to joinNCT06967038 - 2. fázisTaking peopleBCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 18 év to 65 év
- People
- 50
- Run by
- Peking University People's Hospital
See details and how to joinNCT06794008 - No phaseCsak meghívásosUniversal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
- Where
- Shanghai
- Életkor
- 18 év to 65 év
- People
- 15
- Run by
- Bioray Laboratories
See details and how to joinNCT05859997 - 1/2. fázisTaking peopleSequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
- Where
- Beijing
- Életkor
- 21 év to 90 év
- People
- 60
- Run by
- Essen Biotech
See details and how to joinNCT06428188